Shanghai Fosun Pharmaceutical (02196): The registration application for Injection of Dexmedetomidine Tartrate has been approved.

Shanghai Fosun Pharmaceutical (02196) announced that its subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd., a holding company of Shanghai Fosun Pharmaceutical Group, has obtained approval from the National Medical Products Administration for the registration of metaraminol bitartrate injection. The approved indications include the restoration of blood pressure in cases of acute hypotension, as well as the adjunct treatment of cardiac arrest and maintenance of blood pressure after resuscitation from cardiac arrest. This product can also be used as adjunct therapy in cases of shock caused by insufficient blood volume to supplement blood volume during emergency situations to raise blood pressure and temporarily maintain brain and coronary artery perfusion until the effects of volume replacement therapy take place.